phrykt

Niagen Bioscience, Inc. (NAGE): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of NAGE were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Niagen Bioscience

From the latest filings

Overall: about as much buying as selling. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NAGE

138 funds and institutions reported NAGE shares worth $103M at the end of Q2 2026, about 40% of the company. The largest holder is BlackRock, Inc. with 5.2%.

Funds and institutions (13F) 40%Everyone else 60%

10 largest owners, by share of the company

BlackRock, Inc.5.2%
SteelPeak Wealth, LLC4.4%
Vanguard Capital Management LLC2.7%
Tieton Capital Management, LLC2.5%
Qube Research & Technologies Ltd2.0%
Geode Capital Management, LLC1.8%
UBS Group AG1.6%
Goldman Sachs Group Inc1.6%
Arrowstreet Capital, Limited Partnership1.5%
Vanguard Portfolio Management LLC1.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.4.18M5.23%$13.3M+8%
SteelPeak Wealth, LLC3.50M4.37%$11.2M+4%
Vanguard Capital Management LLC2.15M2.68%$6.8M-0%
Tieton Capital Management, LLC2.01M2.51%$6.4M-1%
Qube Research & Technologies Ltd1.63M2.03%$5.2M-5%
Geode Capital Management, LLC1.48M1.85%$4.7M+10%
UBS Group AG1.28M1.60%$4.1M-9%
Goldman Sachs Group Inc1.26M1.58%$4M+1%
Arrowstreet Capital, Limited Partnership1.17M1.46%$3.7M-51%
Vanguard Portfolio Management LLC1.17M1.46%$3.7M-5%
State Street Corp1.08M1.35%$3.5M-0%
Renaissance Technologies LLC659,5840.82%$2.1M-50%
Citadel Advisors LLC630,1090.79%$2M+19%
Dimensional Fund Advisors LP605,3260.76%$1.9M-43%
Morgan Stanley504,7720.63%$1.6M+32%
Victory Capital Management Inc473,3720.59%$1.5M+11%
AQR Capital Management LLC472,0560.59%$1.5M-54%
Sei Investments Co471,9340.59%$1.5M-51%
Northern Trust Corp466,7200.58%$1.5M+18%
Connor, Clark & Lunn Investment Management Ltd.458,6140.57%$1.5M-21%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No NAGE insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NAGE short interest

Moderate short interest. 5.5% of NAGE shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went down 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.35M NAGE shares were sold short, 5.5% of the shares outstanding, up 4.2% from the report before. At the average daily volume of 487,926 shares, buying them all back would take about 8.9 trading days (days to cover).

Shares short, % of all shares

5.49%May 15Oct 306.43%

Days to cover

8.9May 15Oct 3012.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.35M5.49%+4%487,9268.9
Oct 15, 20264.18M5.28%+8%674,9506.2
Sep 30, 20263.87M4.90%-3%392,9849.9
Sep 15, 20264.00M5.05%-4%353,83511.3
Aug 31, 20264.16M5.25%-4%470,6208.8
Aug 14, 20264.31M5.45%-5%805,0855.4
Jul 31, 20264.55M5.74%-5%627,5107.2
Jul 15, 20264.79M5.98%+9%733,0576.5
Jun 30, 20264.39M5.49%-2%789,5565.6
Jun 15, 20264.50M5.62%-5%652,1146.9
May 29, 20264.72M5.89%-5%993,5534.8
May 15, 20264.99M6.23%-8%1.26M4.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Niagen Bioscience company events

Niagen Bioscience filed 8 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 4, 2026ResultsReleased financial results. Filing
  3. Jun 29, 2026VoteReported shareholder vote results. Filing
  4. May 6, 2026ResultsReleased financial results. Filing
  5. Mar 19, 2026AnnouncementOn March 19, the Company issued a press release announcing that the Board of Directors of Niagen Bioscience, Inc. approved an increase in the authorization under the Company’s share repurchase program. Filing
  6. Mar 4, 2026ResultsReleased financial results. Filing
  7. Feb 26, 2026AnnouncementChromaDex, Inc. and ChromaDex Analytics, Inc., each a wholly-owned subsidiary of the Company, and the Company, as guarantor of certain provisions (together with ChromaDex, Inc. and ChromaDex Analytics, Inc., the “Sellers”), entered into an Asset Purchase Agreement with VHG Labs, Incorporated, part… Filing
  8. Dec 22, 2025AgreementChromaDex, Inc., a wholly owned subsidiary of Niagen Bioscience, Inc., executed an assignment agreement with Queen’s University Belfast, with an effective date of December 16, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Niagen Bioscience financials

Famous investors that hold NAGE

4 of the 50 well-known investors we track reported holding NAGE in their latest 13F filing. The largest position is Paul Tudor Jones's, worth $1.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Paul Tudor Jones · Tudor Investment CorpQ3 2026458,933$1.3M0.0%+433%
Jim Simons · Renaissance TechnologiesQ3 2026287,038$838K0.0%-56%
Ken Griffin · Citadel AdvisorsQ3 2026217,931$636K0.0%-65%
Steve Cohen · Point72 Asset ManagementQ3 202626,085$76.2K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Niagen Bioscience, Inc. (NAGE) stock

Who owns the most NAGE stock?

The largest reported owner of Niagen Bioscience, Inc. (NAGE) is BlackRock, Inc., with 5.2% of the company. In total, 138 funds and institutions reported holding NAGE at the end of Q2 2026, together about 40% of the shares. See the largest owners.

Are NAGE insiders buying or selling?

No NAGE insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in NAGE?

As of Oct 30, 2026, 4.35M NAGE shares were sold short, 5.5% of the shares outstanding, up 4.2% from the report before. At the average daily volume of 487,926 shares, buying them all back would take about 8.9 trading days (days to cover). See the history.

Which famous investors hold NAGE?

4 of the 50 well-known investors we track reported NAGE in their latest 13F filing, including Paul Tudor Jones, Jim Simons, Ken Griffin. The largest position is worth $1.3M. See all holders.

Executive pay

Niagen Bioscience's chief executive was paid a total of $8.4M for the year ended Dec 31, 2025, up 592% from $1.2M the year before. In the last 12 months, Niagen Bioscience's executives and directors bought $45.6K of stock on the open market and sold none.

Chief executive, total pay$8.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$10.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$637KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.